New Data Released Confirms Galderma's Nemluvio Enhances Itch Relief and Sleep Within 48 Hours

Clinical Findings on Nemolizumab: Galderma Group AG reported that Nemolizumab significantly alleviated itch and sleep disturbances in patients with atopic dermatitis and prurigo nodularis within 48 hours, based on analyses from phase III clinical trials.

Trial Details: The ARCADIA and OLYMPIA programs involved over 2,200 patients and demonstrated that Nemolizumab reduced itch intensity and improved sleep quality more effectively than placebo.

Approval and Market Performance: Nemolizumab was approved in the US for treating adults with prurigo nodularis and adolescents with atopic dermatitis, generating $263 million in net sales in the first nine months of 2025.

Stock Impact: Following the positive clinical findings and sales performance, Galderma raised its full-year guidance, although its shares experienced a slight decline of 0.93%.